Toronto Dominion Bank Sells 12,950 Shares of Danaher Co. (NYSE:DHR)

Toronto Dominion Bank trimmed its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 3.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 363,402 shares of the conglomerate's stock after selling 12,950 shares during the quarter. Toronto Dominion Bank owned approximately 0.05% of Danaher worth $83,416,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of DHR. LaFleur & Godfrey LLC grew its position in Danaher by 1.5% during the 4th quarter. LaFleur & Godfrey LLC now owns 29,855 shares of the conglomerate's stock worth $6,853,000 after acquiring an additional 440 shares during the last quarter. CX Institutional grew its position in shares of Danaher by 2.1% in the 4th quarter. CX Institutional now owns 2,970 shares of the conglomerate's stock worth $682,000 after buying an additional 62 shares during the last quarter. Geneos Wealth Management Inc. grew its position in shares of Danaher by 2.4% in the 4th quarter. Geneos Wealth Management Inc. now owns 16,713 shares of the conglomerate's stock worth $3,837,000 after buying an additional 399 shares during the last quarter. Cyndeo Wealth Partners LLC grew its position in shares of Danaher by 1.8% in the 4th quarter. Cyndeo Wealth Partners LLC now owns 8,579 shares of the conglomerate's stock worth $1,969,000 after buying an additional 154 shares during the last quarter. Finally, Grimes & Company Inc. grew its position in shares of Danaher by 0.6% in the 4th quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate's stock worth $1,696,000 after buying an additional 43 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Transactions at Danaher

In other news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president now owns 15,179 shares in the company, valued at $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman now owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.20% of the company's stock.

Danaher Stock Down 0.9%

NYSE:DHR traded down $1.64 during trading hours on Friday, reaching $188.83. 960,053 shares of the company traded hands, compared to its average volume of 3,463,136. The business's 50-day moving average price is $193.18 and its two-hundred day moving average price is $214.13. The stock has a market capitalization of $135.14 billion, a P/E ratio of 35.79, a P/E/G ratio of 2.66 and a beta of 0.80. Danaher Co. has a 1 year low of $171.00 and a 1 year high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The business had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Analysts predict that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.68%. Danaher's dividend payout ratio is currently 24.85%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DHR. Jefferies Financial Group cut their price objective on Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a research report on Tuesday, April 22nd. Raymond James reiterated a "market perform" rating on shares of Danaher in a research report on Monday, February 3rd. Royal Bank of Canada reiterated an "outperform" rating and issued a $250.00 price objective on shares of Danaher in a research report on Wednesday, April 23rd. The Goldman Sachs Group cut their price objective on Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Finally, Citigroup restated a "buy" rating on shares of Danaher in a research report on Monday, April 7th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $263.24.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.